Stocks Health care ADAPY

OTC · Health care

Adaptimmune Therapeutics PLC (ADAPY)

Adaptimmune Therapeutics PLC brought in $65.1M of revenue over the twelve months to June 30, 2025, down 54.0% from a year earlier. It posted a net loss of $169.8M. In fiscal 2024 capital spending exceeded operating cash flow by $74.1M. At June 30, 2025 it held $26.1M in cash against $25.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2025.

Watch ADAPY in 60 seconds

What Adaptimmune Therapeutics PLC does

Adaptimmune Therapeutics PLC is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker ADAPY.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Where ADAPY ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Adaptimmune Therapeutics PLC has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. April 22, 2026
   Form RW filing RW
2. February 17, 2026
   Passive stake (5% or more) SCHEDULE 13G
3. November 14, 2025
   Passive stake changed SCHEDULE 13G/A
4. November 13, 2025
   Securities offering prospectus 424B3
5. November 13, 2025
   Deregistration 15-12G
6. October 28, 2025
   Form S-8 POS filing S-8 POS
7. October 28, 2025
   Form S-8 POS filing S-8 POS
8. October 28, 2025
   Form S-8 POS filing S-8 POS
9. October 28, 2025
   Form POS AM filing POS AM
10. October 28, 2025
    Form 25 filing 25

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 8, 2025. Insider transactions on SEC

Insider trades

What the people running Adaptimmune Therapeutics PLC did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about ADAPY

What does Adaptimmune Therapeutics PLC do?

Adaptimmune Therapeutics PLC is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker ADAPY.

Is Adaptimmune Therapeutics PLC profitable?

No. Over the twelve months to June 30, 2025 it reported a net loss of $169.8M on revenue of $65.1M.

How much revenue does Adaptimmune Therapeutics PLC make?

Over the twelve months to June 30, 2025 Adaptimmune Therapeutics PLC reported revenue of $65.1M. That is 54.0% less than a year earlier.

When did Adaptimmune Therapeutics PLC last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2025. It covers the period to June 30, 2025. Its newest filing of any kind is the form RW filing from April 22, 2026.

Similar companies

Compare ADAPY with

Compare ADAPY with any company

Follow ADAPY

Get an email when Adaptimmune Therapeutics PLC files with the SEC: results, executive changes, material agreements and annual reports.

Follow ADAPY: get an email when it files

Where the numbers come from

Financial figures are the values Adaptimmune Therapeutics PLC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.